Larimar Therapeutics Inc LRMR shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug ...
People living with a rare neurological degenerative disease have called on the Government to make the first treatment for the ...
The former Bachelor Australia contestant shared a personal essay Friday for Mamamia, describing what she called mourning a ...
Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...
The Bachelor Australia star shares how embracing grief has helped her focus on meaningful activities and relationships in her ...
Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.
IntraBio Inc. today announced positive results from the full data set for the pivotal Phase III IB1001-303 clinical trial, “Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the agency’s bureaucracy affects innovation, with one witness testifying that ...
Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need to be even stricter with its expenditures. | Biohaven is powering ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results